At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,000 enrolled
Drug / intervention
Omacor (Omega-3-acid ethyl esters)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy
In Brief
An observational study evaluating Omacor (Omega-3-acid ethyl esters) for History of Myocardial Infarction and Hypertriglyceridemia. Completed, enrolled 3,000 participants across 93 sites.
Detailed Summary
A prospective observational program using digital technology tools to enhance patient adherence to Omacor therapy
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedJan 2018
Primary CompletionJul 2019
TodayJul 2026
First PostedJan 30, 2018
Enrollment StartJan 24, 2018
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago
Interventions
Omacor (Omega-3-acid ethyl esters)drug
Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.